Head to Head Analysis: BioCardia (NASDAQ:BCDA) versus Synlogic (NASDAQ:SYBX)

BioCardia (NASDAQ:BCDA) and Synlogic (NASDAQ:SYBX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Earnings & Valuation

This table compares BioCardia and Synlogic”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	N/A	N/A	-$8.23 million	($0.64)	-1.86
Synlogic	$8,000.00	1,791.42	-$23.36 million	($0.06)	-19.50

BioCardia has higher earnings, but lower revenue than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

20.6% of BioCardia shares are held by institutional investors. Comparatively, 63.4% of Synlogic shares are held by institutional investors. 17.4% of BioCardia shares are held by insiders. Comparatively, 2.6% of Synlogic shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and target prices for BioCardia and Synlogic, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1	1	1	0	2.00
Synlogic	1	0	0	0	1.00

BioCardia currently has a consensus target price of $25.00, suggesting a potential upside of 2,000.84%. Given BioCardia’s stronger consensus rating and higher possible upside, equities analysts clearly believe BioCardia is more favorable than Synlogic.

Volatility and Risk

BioCardia has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Synlogic has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500.

Profitability

This table compares BioCardia and Synlogic’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-569.36%	-183.15%
Synlogic	N/A	-26.47%	-18.00%

Summary

BioCardia beats Synlogic on 7 of the 12 factors compared between the two stocks.

About BioCardia

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

About Synlogic

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.